

# Manuel Antonio Espinoza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2186286/publications.pdf>

Version: 2024-02-01

28  
papers

630  
citations

759233

12  
h-index

610901

24  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1271  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. <i>Journal of Hepatology</i> , 2007, 47, 412-417.	3.7	180
2	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003415.	8.4	72
3	The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis. <i>Medical Decision Making</i> , 2014, 34, 951-964.	2.4	67
4	Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. <i>Value in Health</i> , 2019, 22, 739-749.	0.3	47
5	Costs and consequences of chronic pain due to musculoskeletal disorders from a health system perspective in Chile. <i>Pain Reports</i> , 2018, 3, e656.	2.7	30
6	Critical Analysis of Markov Models Used for the Economic Evaluation of Colorectal Cancer Screening: A Systematic Review. <i>Value in Health</i> , 2018, 21, 858-873.	0.3	28
7	Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2010, 20, 1400-1407.	2.1	24
8	Did Socioeconomic Inequality in Self-Reported Health in Chile Fall after the Equity-Based Healthcare Reform of 2005? A Concentration Index Decomposition Analysis. <i>PLoS ONE</i> , 2015, 10, e0138227.	2.5	24
9	Development of a checklist to guide equity considerations in health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e17.	0.5	16
10	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Na <sup>+</sup> ve Patients in Chile. <i>PLoS ONE</i> , 2015, 10, e0141660.	2.5	13
11	Prevalence, burden of disease, and lost in health state utilities attributable to chronic musculoskeletal disorders and pain in Chile. <i>BMC Public Health</i> , 2021, 21, 937.	2.9	10
12	Using Telenephrology to Improve Access to Nephrologist and Global Kidney Management of CKD Primary Care Patients. <i>Kidney International Reports</i> , 2020, 5, 920-923.	0.8	10
13	Evaluation of the Health Assessment Questionnaire Disability Index in Chilean patients with rheumatoid arthritis. <i>Revista Medica De Chile</i> , 2019, 147, 612-617.	0.2	6
14	Impact of a high-risk multimorbidity integrated care implemented at the public health system in Chile. <i>PLoS ONE</i> , 2022, 17, e0261953.	2.5	6
15	Out-of-Pocket Expenditures in Health and Medications in Chile: Comparative Analysis Between 1997, 2007, and 2012. <i>Value in Health Regional Issues</i> , 2018, 17, 202-209.	1.2	5
16	VISIONS OF STAKEHOLDERS ABOUT INSTITUTIONALIZATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHILE: A QUALITATIVE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 303-306.	0.5	4
17	The Value of Further Research: The Added Value of Individual-Participant Level Data. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 273-284.	2.1	3
18	A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile. <i>Pharmacoeconomics - Open</i> , 2021, 5, 635-647.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. <i>Health Economics (United Kingdom)</i> , 2018, 27, e28-e40.	1.7	2
20	Different Alternatives to Assess the Burden of Disease Using Attributable Fraction on a Disability Variable: The Case of Pain and Chronic Musculoskeletal Disorders in Chile. <i>Value in Health Regional Issues</i> , 2021, 26, 15-23.	1.2	2
21	The power of chameleonic ideas in the policy decision-making process: the case of the 'students' revolution' in Chile. <i>Journal of Education for Teaching</i> , 2012, 38, 509-511.	2.0	1
22	Evaluación de tecnologías sanitarias para la toma de decisiones y la rendición de cuentas: una urgente reflexión para el sistema de salud chileno. <i>Value in Health Regional Issues</i> , 2017, 14, 33-34.	1.2	1
23	Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno. <i>Value in Health Regional Issues</i> , 2017, 14, 28-32.	1.2	1
24	Knowledge Translation in Practice: Exploring the Potential Use of MCDA in Central America and the Caribbean. <i>Value in Health Regional Issues</i> , 2018, 17, 148-149.	1.2	1
25	Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 609-617.	1.4	1
26	The impact of hypoglycemia on healthcare costs: a modeling study from Chile. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, , 1-6.	1.4	1
27	Value in Health Regional Issues: Reflections and Challenges After a Decade. <i>Value in Health Regional Issues</i> , 2021, 25, 180-181.	1.2	0
28	Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, , 1-9.	1.4	0